Replimune Group, Inc.
REPL$523M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaWOBURN479 employees
Drugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jan 1, 2027
37wMarket Overview
Stock performance and key metrics
REPL News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Vusolimogene Oderparepvec
Advanced Melanoma
RP2
Metastatic Uveal Melanoma
RP1
Non-Small Cell Lung Cancer (NSCLC)
RP3
Refractory Metastatic Colorectal Cancer
Cemiplimab
Cutaneous Squamous Cell Carcinoma
RP1, intra-tumoral injection, oncolytic virus
Cutaneous Squamous Cell Carcinoma
RP2 Monotherapy
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vusolimogene Oderparepvec | Phase 3 | Advanced Melanoma | - | - |
RP2 | Phase 3 | Metastatic Uveal Melanoma | - | - |
RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
RP3 | Phase 2 | Refractory Metastatic Colorectal Cancer | - | - |
Cemiplimab | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP1, intra-tumoral injection, oncolytic virus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
RP2 Monotherapy | Phase 2 | Hepatocellular Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply